At the beginning of 2022, the attention of the pharmaceutical industry has increased, and more than 460 institutions have received surveys

 At the beginning of 2022, institutional research enthusiasm continued to heat up.
According to statistics, a total of 96 A-share listed companies have ushered in research
.
Among them, pharmaceutical and biological enterprises have received a total of 467 institutional surveys, and their attention has increased, while Huadong Medicine, Xianju Pharmaceutical, and Livzon Group have all received more institutional surveys
.
On January 5, 2022, the East China Pharmaceutical Industry Microbiology Seminar with a market value of 75.
9 billion yuan attracted 285 institutions and individuals including CICC, Bosera Fund, Goldman Sachs Group, Gao Yi Asset, Harvest Fund, etc.
A total of 525 people were surveyed
.
Huadong Medicine said that the company has been deeply engaged in the field of industrial microorganisms for more than 40 years, and has a solid industrial foundation.
It has successfully developed and manufactured a variety of microbial drugs, and built a key technical system for the development and production of microbial products.
The scale and technology of existing microbial fermentation products The level is at the highest level in the industry
.
Excellent industry prospects and market potential are one of the reasons for Huadong Medicine's deep layout in the field of industrial microorganisms
.
It is reported that the main contents of the organization's investigation of Huadong Medicine include the opening speech and the introduction of the guests.
The domestic pharmaceutical industry has undergone great changes in recent years.
The company is actively carrying out innovation and international transformation.
At the same time, the development model of the original raw material business is also actively Explore and change
.
Since 2020, the company has actively explored the transformation from a production center to a profit center.
The manufacturing and CMC (including subsidiaries) centers have changed the original positioning concept of internal support, benchmarked against the international market, launched the CMO/CDMO model, and actively participated in the international market competition etc.

_ On January 6, 2022, Xianju Pharma released a record form of investor relations activities.
The company received surveys from 63 institutions on January 5, 2022.
The types of institutions are insurance companies, others, fund companies, securities companies, and sunshine private equity institutions.

.
During the survey, regarding investors' questions about Xianju Pharmaceutical's medium and long-term strategic positioning, Xianju Pharmaceutical stated that the company will focus on the field of steroid hormones for a long time, complete and refine the hormone industry chain, and continuously enrich the product structure of APIs and preparations.
Focus on comprehensive ability improvement
.
In response to the company's research and development, Xianju Pharmaceutical stated that the company will establish product groups in various therapeutic fields through market research and positioning to find and obtain the desired potential products, so as to ensure the company's continued stability in the next 5-10 years.
Develop product reserves
.
At present, the main research products are based on market space and company opportunities, and benchmark the original research product pipeline with a good competition pattern
.
The company has 22 varieties of consistency evaluation, of which 9 have been declared and 4 have been over-rated; 18 new imitation varieties have been declared, 6 of which have been declared
.
According to statistics, Livzon Group has received 8 institutions, 11 fund managers and researchers for three consecutive days, including Zhao Bei, the star fund manager of the public offering giant ICBC Credit Suisse, Zhu Baili, the investment manager of large private equity Telford Capital, and He Shan, the fund manager of Senrui Investments.

.
Investor survey minutes show that Livzon Group has comprehensively deployed a wealth of products in the digestive tract, assisted reproduction, and spiritual fields.
Strong support
.
Livzon Group said that as the products under development of the company's biological drug platform and complex preparation platform gradually enter the mid-to-late clinical stage, the company's innovative research and development will also enter the harvest period
.
The company's recombinant human chorionic gonadotropin for injection has been approved for marketing, including triptorelin acetate microspheres for injection (one-month sustained release), recombinant humanized anti-human IL-6R monoclonal antibody injection and cetriline acetate for injection Rick has all reported production, and will provide new increments for the company's performance in the past one or two years
.
In addition, the concept of traditional Chinese medicine, the concept of vaccine and the concept of anti-Helicobacter pylori that have continued to be hot recently, Livzon Group has deployed corresponding products, and the outbreak potential is huge
.